Analyst Price Targets — OM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 12:28 pm | Marie Thibault | BTIG | $15.00 | $4.54 | TheFly | Outset Medical price target lowered to $15 from $17 at BTIG |
| January 7, 2026 12:35 pm | Rick Wise | Stifel Nicolaus | $8.00 | $4.29 | TheFly | Outset Medical price target lowered to $8 from $14 at Stifel |
| December 17, 2025 1:50 pm | Shagun Singh | RBC Capital | $7.00 | $4.02 | TheFly | Outset Medical price target lowered to $7 from $17 at RBC Capital |
| November 11, 2025 9:57 am | Rick Wise | Stifel Nicolaus | $14.00 | $12.07 | StreetInsider | Outset Medical Inc. (OM) PT Lowered to $14 at Stifel |
| July 14, 2025 11:31 am | Marie Thibault | BTIG | $37.00 | $19.92 | TheFly | Outset Medical price target lowered to $37 from $45 at BTIG |
| March 21, 2025 6:49 pm | Rick Wise | Stifel Nicolaus | $15.00 | $10.05 | TheFly | Outset Medical price target adjusted to $15 at Stifel after reverse stock split |
| August 8, 2024 3:56 am | Shagun Singh | RBC Capital | $3.00 | $3.40 | StreetInsider | RBC Capital Downgrades Outset Medical Inc. (OM) to Sector Perform |
| June 21, 2024 6:20 am | Shagun Singh | RBC Capital | $6.00 | $3.59 | TheFly | Outset Medical upgraded to Outperform at RBC on expected return to growth |
| April 17, 2024 10:55 am | Rick Wise | Stifel Nicolaus | $6.00 | $2.27 | StreetInsider | Stifel on Outset Medical Inc. (OM): 'we expect this home hemodialysis agreement will be a positive incremental sales driver in 2025 and beyond' |
| April 8, 2024 6:12 am | Maria Thibault | BTIG | $6.00 | $2.05 | StreetInsider | BTIG Starts Outset Medical Inc. (OM) at Buy |
Latest News for OM
Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript
Outset Medical NASDAQ: OM reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new $40 million refresh agreement with HCA Healthcare.
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.84 per share a year ago.
SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the second quarter ended June 30, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OM.
U.S. House Trading
No House trades found for OM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.